Impact of COVID-19 on FDA Enforcement and Approvals – Part 5 – FDA Provides Update to Shape Expectations on New Approvals
Eye on FDA
APRIL 17, 2020
In response to written questions submitted last month regarding the potential for delays, FDA had stated that “ CDER remains fully capable to continue daily activities, while responding to the public needs of the current COVID-19 outbreak. ” In a subsequent blog posting this month, it was noted that FDA was devoting personnel to focus on COVID-19-related review efforts and that it was certainly possible that this might be a factor in delaying new approvals of non-COVID-19 medicines a
Let's personalize your content